Monospecific polyclonal antisera were raised in guinea-pigs against the calf rotavirus polypeptides VP 1, VP2, VP3* + 4*, VP4.2, VP6, VP7. I, VP7.2 and VP 10. All of the antisera gave a similar pattern of cytoplasmic immunofluorescence in rotavirus-infected cells, but spots of fluorescence of varying intensity with different sera were seen over the nucleus. Immune precipitation, using Staphylococcus aureus to collect immune complexes, showed that VP2 was precipitated by antiserum to VP2 (ct-VP2) and VP6 by ct-VP6, ct-VP7.1 and ct-VP7.2 both precipitated the same range of proteins from infected cells (VP7, VP7.1 and VP7.2) or from virions (VP7.1 and VP7.2). VP 10, either from virions or infected cells, was not precipitated by a-VP 10. The only antiserum which efficiently neutralized infectivity was a-VP7.2. There were low levels of neutralization with a-VP10 (but the results varied from experiment to experiment) and traces with a-VP6, ct-VP7.1 and the other antisera did not neutralize even though a-VP7.1 agglutinated double-shelled particles as seen in immune electron microscopy to a greater extent than ~-VP7.2. Both VP7.1 and VP7.2 were shown to be glycoproteins by tunicamycin treatment of infected cells. Core particles only were agglutinated by a-VP10. All the evidence leads us to conclude that there were major neutralizing antigenic determinants present on VP7.2, a minor component of the outer shell of the virion.
INTRODUCTION
Rotaviruses are a ubiquitous group belonging to the reovirus family which infect every mammalian species that has been investigated, and also many avian species (Woode et al., 1976; McNulty et al., 1979) . Each species appears to have at least one unique serotype, and human rotaviruses have been divided into three serotypes (Woode et aL, 1976; Thouless et al., 1977 Flewett et al., 1978; Yolken eta/., 1978; Zissis & Lambert, 1978 Beards et al., 1980; Zissis et al., 1981) . Recently, at least one new major group that does not react serologically with other rotavirus antisera has been described (Saif et al., 1980; McNulty et aL, 1981; Bridger et at., 1982) . All rotaviruses cause acute infantile gastroenteritis in young animals and therefore pose an important medical and economic problem. Since it would be very useful to have a heterospecific vaccine, information about the functions of the major virus antigens is of primary interest.
The virus genome is composed of 11 separate segments of double-stranded RNA (Rodger et al., 1975; Kalica et al., 1978) . Rotavirus polypeptides in virions and in infected cells have been studied by several groups (Thouless, 1979; Kalica & Theodore, 1979; Matsuno & Mukoyama, 1979; Clark et al., 1981; Espejo et al., 1981; Estes et al., 1981; McCrae & Faulkner-Valle, 1981; Novo & Esparza, 1981) , and at least five polypeptides and three cleavage products have been identified in virus particles, but there is still disagreement concerning the total number and origins of the polypeptides. No functions have been assigned to any of the virus polypeptides, although a recent study on reassortant viruses has assigned 0022-1317/82/0000-5156 $02.00 © 1982 SGM the neutralization antigen to the ninth gene segment in human rotavirus and the eighth or ninth segment in calf rotavirus and a subgroup specificity to the sixth gene segment Kalica et al., 1981) . Segment 6 encodes the major core protein (VP6) and segments 7, 8 and 9 encode VP7, 8 and 9, although the individual assignments are unknown (Smith et al., 1980; Dyall-Smith & Holmes, 1981 a) . This paper describes a study of the antigenic activities of a number of individual rotavirus polypeptides as determined by their reaction with monospecific polyclonal antisera. The antigen responsible for neutralization is identified as VP7.2. Our results will be discussed in relation to the finding of a recently published study by Bastardo et al. (1981) on the same problem.
METHODS
Cells and virus. The U.K. tissue culture-adapted calf rotavirus was passed 28 times in primary calf kidney cells and 19 times in LLCMK2 cells. Virus was also purified from the faeces of a gnotobiotic calf which had been infected with the same strain from Dr J. Bridger (ARC Institute for Research on Animal Diseases, Compton, Newbury, Berks, U.K.). BSC-1 African green monkey kidney cells were grown in Glasgow's modified Eagle's medium plus 5 % (v/v) foetal calf serum and infected with rotavirus at 0.03 to 0.1 p.f.u./cell. Virus was grown for 48 h at 37 °C in serum-free medium containing 10/~g/ml trypsin (type III, 2 × crystallized; Sigma). Virus was quantified by a standard plaque assay using a serum-free medium plus 1% agar overlay (Faulkner-Valle et al., 1982) . After 3 days incubation at 37 °C cell sheets were fixed and, after removing the overlay, were stained with 0.1% crystal violet in 20% ethanol. At this stage 'plaques' appear as areas which stain more intensely than non-infected cells. These lyse into clear plaques later in infection.
Virus purification. Rotavirus was purified from infected cells as described by McCrae & Faulkner-Valle (1981) . Equilibrium CsC1 gradients were centrifuged at 100000 g for 18 h in an MSE 10 × 10 ml angle rotor. Single-shelled particles (cores) banded at a density of 1.38 g/ml and double-shelled particles at 1.36 g/ml. Cores were also prepared by treatment of virions with 1.5 mM-EDTA for 30 min at 37 °C and collected by centrifugation through 45 % sucrose at 100000 g for 90 min.
Radiolabelling of virus-induced polypeptides in infected cells. Confluent monolayers of BSC-1 cells in 30 mm Petri dishes were infected at 5 p.f.u./cell. After adsorption for 1 h at 37 °C, the inoculum was removed and replaced with medium containing 1% of the normal amount of methionine. Cells were labelled at 6 h post-infection with 500 /ICi/ml [35S]methionine (800 to 1200 Ci/mmol, Amersham International) in phosphate-buffered saline (PBS) for 30 min at 37 °C. The cells were then scraped off into TNE buffer (10 mM-Tris, l0 mM-NaC1, 1 mM-EDTA pH 7.4). After 10 min on ice, 1% Nonidet P40 (NP40) was added for l0 min and the cells were then disrupted in a Dounce homogenizer with 20 strokes, centrifuged at 14000 g for 1 min and the supernatants stored at -20 °C. In experiments with tunicamycin, which inhibits glycosylation (Schwarz et al., 1976) , cells were maintained in the presence of 5 /~g/ml tunicamycin throughout the infection and labelling period.
[35S]methionine-labelled rotavirus for purification was prepared by infecting roller bottles of methionine-starved BSC-1 cells at 1 p.f.u./cell and incubating for 48 h at 37 °C in medium containing 10% of the normal concentration of methionine, 20 /~Ci/ml [35S]methionine and 10/~g/ml trypsin. Purified rotavirus was radiolabelled with x2~I by the chloramine T method of Syvanen et al. (1973) . Virus was pelleted at 100000 g for 90 min through 45 % sucrose to separate it from free x251.
Immune precipitation. Immune precipitation of rotavirus proteins was carried out using a modification of the method of Kessler (1975) . Cell extracts and antiserum were incubated in an excess of detergent buffer [100 mM-Tris-HC1 pH 8.2, 100 mu-KC1, 5 mM-MgC12, 1%
Triton X-100, 1% (w/v) sodium deoxycholate, 0.5% (w/v) SDS] for 1 h at room temperature and then incubated with formalin-fixed Staphylococcus aureus Cowan I strain in the same buffer for 18 h at 4 °C with stirring. A refinement of this method was to denature the proteins in the infected cell extract in 2% (w/v) SDS and 5 % fl-mercaptoethanol (BME) at 100 °C for 2 rain before dilution in detergent buffer, which was found to reduce non-specific precipitation. The precipitates were centrifuged and then washed once in the same buffer. The precipitated proteins were then solubilized with 2% (w/v) SDS and 5 % BME at 100 °C for 5 rain before analysis by polyacrylamide gel electrophoresis.
Polyaerylamide gel eleetrophoresis (PAGE) . The Laemmli (1970) discontinuous buffer system was used. Proteins were separated on a I0 to 30% linear acrylamide gradient as described by Cook et al. (1979) . Fluorography was carried out as described by Bonner & Laskey (1974) using Kodak X-Omat H film.
Preparation of individual rotavirus polypeptides and immunization of guinea-pigs.
Rotavirus was purified and sufficient [35S]methionine-labelled or t25I-labelled rotavirus was added so that polypeptides could be located after PAGE as described above. Proteins from approx. 1 mg of purified rotavirus (from 30 to 40 roller bottles) were used for each injection. Gels were washed, dried and exposed to film, and the radioactive bands were cut out and swollen in Tris-NaC1 pH 7.4 for 18 h at 4 °C. The acrylamide gel was then syringed through 13 g, 15 g and 17 g gauge hypodermic needles consecutively and homogenized with adjuvant. Freunds complete adjuvant (Grand Island Biological Co., Grand Island, N.Y., U.S.A.) was used for the first injection and Freund's incomplete adjuvant for subsequent injections. Antigen was injected subcutaneously into young female guinea-pigs, 450 to 550 g each (Duncan-Hartley strain; Olac 1976 Ltd., Bicester, Oxon, U.K.), which had been previously screened and shown to be negative for the presence of rotavirus antibody. Injections were repeated at 3-week intervals until an antibody response was detected by immunofluorescence or immunoprecipitation. Test bleeds were taken from the ear, and the final bleeds were taken from the heart. Blood was allowed to clot at 4 °C overnight and the serum recovered by centrifugation. A convalescent rotavirus antiserum (G203) from a gnotobiotic calf infected with the strain of calf rotavirus used in this study was kindly supplied by Dr J. Bridger.
Plaque reduction assays. Neutralization of calf rotavirus by guinea-pig monospecific antisera or calf anti-calf rotavirus antiserum was determined by a standard plaque reduction assay. Virus and dilutions of antiserum were incubated for 2 h at 25 °C and the residual infectious virus titrated. After adsorption of virus for 1 h at 37 °C, the cell sheets were washed three times to remove residual serum and the cells were then overlaid with a serum-free agar overlay as described above.
Purification of immunoglobulin.
Immunoglobulin was prepared from serum by affinity chromatography on columns of protein A-Sepharose CL-4B (Pharmacia). The columns were washed with PBS until no more protein was released, and then washed with 2 ml PBS containing 1% NP40 followed by more PBS until no protein was detected in the eluate. The purified antibody was then eluted from the column with 150 mM-NaC1, 0.6 % acetic acid pH 3, and the amount of antibody protein was determined at A2s o. Peak fractions were neutralized with KOH and stored at -20 °C. ~zsI-labelled antibody was prepared by lactoperoxidase-catalysed iodination (Marchalonis, 1969) and separated from free iodine by protein A-Sepharose chromatography.
Immunofluoreseenee. Indirect immunofluorescence was performed on cell monolayers on glass coverslips. The fluorescence was observed in a Reichart Binolux II microscope.
Immune electron microscopy (IEM).
Virus from faecal extracts was partly purified by centrifugation at 5000 g for 20 min, and the virus was concentrated from the supernatants by centrifugation at 100000 g for 90 min. Tissue culture-adapted rotavirus was purified as described above. Virus from faecal extracts or tissue culture fluid was mixed with antiserum (1/10 dilution) and incubated for 2 h at room temperature. The mixtures were then applied to carbon-coated electron microscope grids, allowed to almost dry, and then washed three times in distilled water with drying between each wash on filter paper. Virus was negatively stained with potassium phosphotungstate and then examined in a Jeol 100CX or Philips EM 200 electron microscope for aggregation of virus particles.
RESULTS

Preparation of antigen for immunization, and development of response in guinea-pigs
Identification of polypeptides separated by PAGE is shown in Fig. 1 . Polypeptides VP1, VP2, VP3, VP3*, VP4* and VP6 were present in [35S]methionine-labelled cores, VP2 and VP6 being the major species. Similarly labelled double-shelled virus particles contained, in addition, VP4.2, VP7.1, VP7.2, VP10 and a polypeptide we call 4.3 of mol. wt. about 20000. 12~I labelling confirmed the presence of VP4.2 and VP10 and revealed an additional polypeptide, VP5*. In addition, non-structural proteins VP8 and VP9 were found in infected cells (Fig. 1) , and VP5, which was not detected in Fig. 1 , can be seen in Fig. 6 . Controversy surrounds the origin and location of some of these polypeptides (Espejo et al., 1981; Estes et al., 1981; Dyall-Smith & Holmes, 1981b; McCrae & Faulkner-Valle, 1981) , particularly VP2, VP3, VP4, VP7, VP8 and VP10, and we have summarized the current situation with regard to our own work and that of others in Fig. 2 . Some of the evidence, particularly relating to the data on tunicamycin-treated cells, is contained below in this report. In trypsin-treated simian rotavirus, VP3 is completely cleaved into VP4.2 and VP4.3, a polypeptide of mol. wt. 28 000 (Estes et al., 1981) . Dyall- Smith & Holmes (1981 b) agree that VP3 (probably p84) and VP4.2 (p62) have peptides in common but did not observe VP4.3. In calf rotavirus, Clark et al. (1981) reported an estimated mol. wt. of 20000 for this small polypeptide, but it should be noted that they have claimed molecular weights consistently lower than those reported elsewhere (Thouless, 1979; McCrae & Faulkner-Valle, 1981; Novo & Esparza, 1981) for the lower molecular weight proteins. Some VP2 is cleaved into the products VP3* and VP4*, i.e. VP3* is a different gene product to VP3 (Estes et al., 1981) . VP5* is also thought to be a cleavage product of VP2 and unrelated to VP5 (Estes et al., 1981) . DyaU- Smith & Holmes (1981b) did not directly compare peptides of VP2 and VP5* (p57), although they conclude that each was unique. VP7 is a glycoprotein which exists in at least three forms and is derived from a polypeptide which migrates slightly faster than VP9 (McCrae & Faulkner-Valle, 1981) . The VP8 seen in virus particles by McCrae & Faulkner-Valle (1981) has been shown by peptide mapping to be a variant of VP7 (Espejo et al., 1981) . These authors also showed that there were two forms of VP7 present in virions, which we have called VP7.1 and VP7.2. VP7.2 migrates in the position of VP8 of McCrae & Faulkner-Valle (1981) but the 'true' VP8 from infected cells is a non-structural protein (Espejo et al., 1981) . While Dyall- Smith & Holmes (1981 b) agree that VP7 and VP7.1 are related (p36 and gp34), they do not distinguish between VP7.2 (p33) and VP8, VP9 and vpr7 which appear to be lumped together as p31. This explains why they find that p34, p33 and p31 are related. Virion VPI0 is thought to be the same as the glycosylated VPI0 seen in infected cells (McCrae & Faulkner-Valle, 1981) , although a cleavage product of VP3 with a similar molecular weight to VP10 has been described for simian rotavirus (Estes et al., 1981) . The molecular weight of this cleavage product may be lower in calf rotavirus (Clark et at., 1981) and VP4.3 may be this cleavage product. The amount of VP 10 was found to vary: for instance there is little in Fig. 1 but more in Fig. 3 and 6 . We do not always see VP 11, which is a minor polypeptide in infected cells (McCrae & Faulkner-Valle, 1981) .
Polypeptides VP1, VP2, VP4.2, VP6, VP7.1, VP7.2 and VP10 were used to immunize guinea-pigs. VP3* and VP4* were excised and injected together. Samples of serum were taken from guinea-pigs after each injection and screened by immunofluorescence and immune precipitation for the presence of specific antibody (Table 1) . Injections were continued and if the immune response reached a plateau a final bleed was taken. Fig. 3 shows that a-VP2 precipitated only VP2, and that this protein was also precipitated by ~-VP3*,4*, which are thought to be cleavage products of VP2 (Estes et al., 1981) . a-VP6 precipitated only VP6. a-VP7.2 both precipitated a major polypeptide co-migrating with VP7 (which is resolved in Fig. 6 into VP7 and VP7.1) and two minor polypeptides, the lower of which co-migrated with VP7.2. a-VP7.1 and a-VP7.2 both precipitated VP7.1 and VP7.2 to the same extent when purified virus was used as the source of antigen, a-VP10 did not precipitate VP 10 from infected cells. On one occasion it precipitated small amounts of VP2 but this was not seen in repeat experiments. There were no precipitates with a-VP1 and a-VP4.2 apart from the trace amounts which appeared in all samples. As VP4.2 and VP10 may be present in undetectable amounts in infected cells, [35Slmethionine-labelled purified virus was also used as antigen in immune precipitation. This gave the same pattern of The antibody response to VP3*,4* was shown by immune precipitation to be directed against VP2; all others were specific for the immunogen used. precipitation as with infected cell extracts (data not shown). The lack of precipitation of a-VP10 was investigated further since this antiserum gave strong immunofluorescence (see below). Antigen was prepared and immune complexes precipitated in buffer containing 0.5 % NP40 only, as we thought it possible that binding of VP10 to a-VP10 may have diminished. Again, there was no precipitation. Table I summarizes the development of antibody as determined by the immunofuorescence reaction. The pattern of immunofluorescence seen with each of the monospecific antisera was very similar. In all cases immunofluorescence was predominantly cytoplasmic and mainly in the perinuclear region with a patchy distribution. There was no fluorescence with preimmunization serum. Some fluorescent spots were seen over the nucleus, especially with a-VP6 (Fig. 4 b) . A dilution series of each antiserum gave an indication of their potency in this test, with 50% maximum fluorescence occurring with a-VP2, a-VP6 and a-VP7.2 at 1/330, ~-VP7.1 at 1/100 and ct-VP10 at 1/33. Unfixed cells were also examined for the presence of antigens on the plasma membrane but none was detected. Table 2 shows that antiserum G203 against whole virus gave 99.9% neutralization while the only clear cut neutralization with monospecific antiserum (99 %) was seen with a-VP7.2. a-VP 10 gave a variable amount of neutralization (60 to 90%) and a-VP6 reduced infectivity by 50 %. Ultrasonication immediately prior to the titration of neutralized virus did not affect the titre, indicating that the reduction of infectivity was not caused by the antisera aggregating virus particles, a-VP7.1, which precipitated the identical pattern of polypeptides to a-VP7.2, did not neutralize. A time course of virus neutralization with a-VP7.2 is shown in Fig. 5 . Neutralization assays were also performed with pairwise combinations of all the antisera and although neutralization by a-VP7.2 was not enhanced by mixing with a-VP7, i, ¢x-VP6 or ct-VP 10 there was significant blocking of neutralization by a-VP6 (10-fold) and ct-VP 10 (100-fold). Neutralization of calf rotavirus infectivity by a-VP7.2 was reduced by heating at 56 o C ~" Neutralization was carried out with a low dose of virus (50 p.f.u./plate, expt. 1) and a high dose of virus (4 x 104 p.f.u./plate, expt. 2) and serum diluted 1/20. ND, Not done. § u-VPI0 gave a variable percentage of neutralization in different experiments. The value was unaffected by ultrasonication immediately before the titration and was therefore not the result of antibody-mediated aggregation.
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for 30 min. Complete neutralizing activity was restored by addition of guinea-pig complement. Purified a-VP7.2 immunoglobulin neutralized the virus by 90% and was heat stable. Thus, neutralization is enhanced by complement, but is not completely dependent upon it (data not shown).
Determination of the amount of a-VP7.1 and ~-VP7.2 binding to virus particles
We investigated whether or not the neutralizing property of ~-VP7.2 was the result of the ability of the virus to bind greater amounts of a-VP7.2 than a-VP7.1 by adding an excess of 125I-labelled monospecific antiserum to purified double-shelled virus particles. Table 3 shows that approximately three times more ct-VPT. 1 bound to virus than did ct-VP7.2; thus, binding was inversely related to neutralizing activity.
Identification of rotavirus glycoproteins by immune precipitation of tunicamycin-treated cells
These experiments were undertaken to characterize the proteins precipitated by a-VP7.1 and a-VP7.2. In infected cells treated with tunicamycin, VP7 was absent, suggesting that it is glycosylated, and an additional smaller polypeptide migrating ahead of VP9 could be seen * A 50 gg amount of 12~I-labelled Ig (1.5 x 106 ct/min in each case) was mixed with 5 gg formalin-fixed purified rotavirus in a final vol. of I ml PBS. After 18 h at 4 °C with stirring, the virus-antibody complexes were separated from free 12SI-labelled Ig by centrifugation through 45 % sucrose for 90 min at 100000 g. (Fig. 6) . The latter would be the vpr7 o f M c C r a e & Faulkner-Valle (1981) . a -V P 7 . 1 and a -V P 7 . 2 precipitated the same proteins from infected cells, and tides which resolved as two minor species co-migrating with vpr7; however, precipitation was inefficient. Fig. 6 also confirms that VP10 is glycosylated and that its precursor is VP12 (McCrae & Faulkner-Valle, 1981) . These data are included in the summary shown in Fig. 2 .
Reaction of monospecific antisera with calf rotavirus as studied by IEM
After reaction with antiserum against whole calf rotavirus, aggregates of either complete particles or of virus cores, but not mixed aggregates, were observed, a-VP7.1 and a-VP7.2 aggregated complete particles, although the neutralizing a-VP7.2 was less effective. This may be related to the smaller amount of VP7.2 present in virions (see Fig. 1 ) or to the expression in the virion of different or differing amounts of antigenic determinants, and is consistent with greater amounts of a-VP7.1 bound to virus (Table 3) . a-VP10 aggregated core particles only (Fig. 7) . Since VP10 is believed to be a minor protein in the outer shell (see above), one possible interpretation is that VP 10 is attached to naturally occurring cores but is removed by EDTA treatment. However, cores prepared by treatment with EDTA were still agglutinated by a-VPI0, a-VP2 and a-VP6 aggregated neither complete particles nor cores, indicating that the relevant determinants were not expressed (Table 4) . Aggregated particles are illustrated in Fig. 7 . Table 5 summarizes the properties of the antisera used in this report. Antisera against the two major core proteins precipitated the appropriate polypeptides (VP2 and VP6) monospecifically from infected cells and reacted with rotavirus antigen by indirect immunofluorescence, but caused no aggregation as determined by IEM. Apparently, the antigenic determinants of these polypeptides which are seen by our antisera are poorly exposed on the surface of rotavirus cores. Other determinants with subgroup specificity are expressed by VP6 . Bastardo et al. (1981) found that ct-VP6 agglutinated core particles as visualized by electron microscopy, but they provide no criterion of the specificity of their antibody, wVP3* + 4* precipitated only VP2. This is in agreement with Estes et al. (1981) that proteins VP3* and VP4* are protease cleavage products of VP2, although we cannot rule out the possibility that our VP3* + 4* immunogen was contaminated with VP2. a-VPT. 1 and a-VP7.2 both precipitated the glycoproteins VP7, VP7.1 and VP7.2 from infected cells (the latter being confirmed by precipitation from virions) as well as the non-glycosylated precursor(s) vpr7. We identified VP7.2 (as defined in Fig. 1 ) as a major neutralization-specific antigen while ~-VP7.1 had no neutralizing activity. In terms of total protein, VP7.2 is a minor and VP7.1 a major protein of the outer shell (data not shown).
DISCUSSION
Binding of x25I-labelled (t-VP7.1 and 125I-labelled a-VP7.2 confirmed this difference in antigenic terms, and IEM showed that a-VP7.1 was the more effective at agglutinating double-shelled particles. Titration of a-VP7.1 and a-VP7.2 by immunofluorescence showed them to have similar titres. Thus, a-VP7.1 can be classed as a non-neutralizing antibody.
Since a-VP7.1 and a-VP7.2 distinguish between VP7.1 and VP7.2 in virus particles, but immunoprecipitate the same polypeptides from infected cells we conclude that VP7.2 expresses unique antigenic determinants in the virion which are specific for neutralization. The recent study by Bastardo et aL (1981) claimed that their ct-VP6, a-VP7 and ct-VP10 neutralized virus, but because they cite no evidence of the specificity of the antisera and do not distinguish between the two forms of VP7 found in virions, their results are difficult to compare with our own. However, we agree that neutralization is mediated through a protein in the 'VP7 region'. Since our a-VP6 and their ct-VP6 activities differ with regard to immune electron microscopy we cannot comment about neutralization. With a-VP 10 we found a low and variable neutralizing activity, ct-VP10 did not precipitate VP10 (which by the criteria of Fig. 1 is apparently an outer shell protein) from infected cells but showed strong immunofluorescence and reacted strongly with cores and not with complete particles in IEM. This antiserum also has some genuine neutralizing activity which was not the result of aggregation of virus. These results suggest that VPI0 is attached to cores and protrudes through the outer shell, although in a poorly antigenic form. With such a small amount of protein as VP10 it is possible that its apparent absence from cores ( Fig. 1 ) may just reflect a quantitative difference from double-shelled particles. VP 10 is thus analogous to the reovirus 22 polypeptide (Hayes et al., 1981) . Using monoclonal antibodies against reovirus polypeptides, Hayes et al. (1981) found that ct-al, ct-a3 and ~-22 all neutralized reovirus infectivity, although a 1 was responsible for type-specific neutralization in reassortant viruses (Weiner & Fields, 1977) . At present, we have not determined neutralization with our monospecific sera of any other serotype of rotavirus, but experiments to determine the cross-reactivity of these monospecific antisera by enzyme-linked immunosorbent assay are currently underway.
We are grateful to Dr M. Thouless for the tissue culture-adapted calf rotavirus, to Dr J. Bridger for antiserum and calf rotavirus, and to Dr Hamill, Eli Lilley, U.S.A. for the tunicamycin. Dr T. H. Flewett provided invaluable help and advice with the electron microscopy. H.M.K. was supported by a Medical Research Council Studentship.
